Prospective Study to Evaluate Early Proctologic Effects of GLP-1 Receptor Agonists in Morbid Obesity

Morbid obesity is a complex condition associated with numerous comorbidities, including various proctologic diseases like hemorrhoids, anal fissures, and incontinence. The increasing use of GLP-1 receptor agonists (GLP-1 RAs) for weight management and type 2 diabetes has highlighted the need to comprehensively understand their full spectrum of effects. While GLP-1 RAs are well-known for their metabolic benefits, their potential impact on gastrointestinal function extends beyond common side effects like nausea and constipation, warranting investigation into less-explored areas such as anorectal health. This study aims to address this gap by prospectively evaluating these effects.

This prospective observational cohort study will assess the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo comprehensive anorectal symptom assessment and proctologic examination at baseline and again after 3 months of GLP-1 RA treatment. The primary objective is to evaluate the development of newly acquired proctologic diseases and any changes in the severity of pre-existing symptoms. The study design does not include a specific control arm or predefined GLP-1 RA compound or dosage, reflecting a real-world observational approach to patient management.